AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (187.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Molecular testing for acute myeloid leukemia

Moffitt Cancer Center, Tampa, FL 33612-9416, USA
Show Author Information

Abstract

In the era of personalized medicine, information on molecular change at the gene level is important for patient care. Such information has been used for disease classification, diagnosis, prognosis, risk stratification, and treatment, which is especially important in cancer patient care. Many molecular tests exist and can be used to detect the molecular changes at gene level. These tests include, but are not limited to, karyotyping, endpoint polymerase chain reaction (PCR), real-time PCR, Sanger sequencing, pyrosequencing, next-generation sequencing, and so forth. How to use the right tests for the right patients at the right time is essential for optimal patient outcome. This review puts together some information on molecular testing for acute myeloid leukemia.

Keywords

next-generation sequencingtestMolecularacute myeloid leukemia

References

1
Swerdlow SH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, editors. Lyon: International Agency for Research on Cancer; 2017. p. 586.
2

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374: 2209-21.
Crossref Google Scholar
3

Greenland NY, Van Ziffle JA, Liu YC, Qi Z, Prakash S, Wang L. Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia. Hum Pathol. 2020; 108: 76-83.
Crossref Google Scholar
4

Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116: 354-65.
Crossref Google Scholar
5

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016; 540: 433-7.
Crossref Google Scholar
6

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019; 17: 721-49.
Crossref Google Scholar
7

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129: 424-47.
Crossref Google Scholar
8

Clark MM, Hildreth A, Batalov S, Ding Y, Chowdhury S, Watkins K, et al. Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation. Sci Transl Med. 2019; 11: eaat6177.
Crossref Google Scholar
9

Yoest JM, Shirai CL, Duncavage EJ. Sequencing-based measurable residual disease testing in acute myeloid leukemia. Front Cell Dev Biol. 2020; 8: 249.
Crossref Google Scholar
10

Hiatt JB, Pritchard CC, Salipante SJ, O’Roak BJ, Shendure J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 2013; 23: 843-54.
Crossref Google Scholar
11

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018; 132: 1703-13.
Crossref Google Scholar
12

Waalkes A, Penewit K, Wood BL, Wu D, Salipante SJ. Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. Haematologica. 2017; 102: 1549-57.
Crossref Google Scholar
13
Patkar N, Kakirde C, Shaikh AF, Salve R, Bhanshe P, Chatterjee G, et al. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia. 2021. Doi: 10.1038/s41375-021-01131-6. Online ahead of print.
Crossref
14

Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, et al. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14: e0224097.
Crossref Google Scholar
15
Ahn JS, Kim T, Jung SH, Ahn SY, Jung SY, Song GY, et al. Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. Bone Marrow Transplant. 2020. Doi: 10.1038/s41409-020-01165-x. Online ahead of print.
Crossref
16

Ghannam J, Dillon LW, Hourigan CS. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. Br J Haematol. 2020; 188: 77-85.
Crossref Google Scholar
17

Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020; 587: 477-82.
Crossref Google Scholar
18

Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020; 11: 5327.
Crossref Google Scholar
19

Burgess DJ. Spatial transcriptomics coming of age. Nat Rev Genet. 2019; 20: 317.
Crossref Google Scholar
20

Moor AE, Itzkovitz S. Spatial transcriptomics: paving the way for tissue-level systems biology. Curr Opin Biotechnol. 2017; 46: 126-33.
Crossref Google Scholar
21

Vickovic S, Eraslan G, Salmen F, Klughammer J, Stenbeck L, Schapiro D, et al. High-definition spatial transcriptomics for in situ tissue profiling. Nat Methods. 2019; 16: 987-90.
Crossref Google Scholar
22

Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016; 7: 48832-41.
Crossref Google Scholar
23

de Melo-Silva AJ, Lucena JP, Hueneburg T. The evolution of molecular diagnosis using digital polymerase chain reaction to detect cancer via cell-free DNA and circulating tumor cells. Cell Biol Int. 2020; 44: 735-43.
Crossref Google Scholar
24

Gaspersic J, Videtic Paska A. Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice. Biochem Med (Zagreb). 2020; 30: 030504.
Crossref Google Scholar
25

Gorgannezhad L, Umer M, Islam MN, Nguyen NT, Shiddiky MJA. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. Lab Chip. 2018; 18: 1174-96.
Crossref Google Scholar
26

Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021; 73: 422-36.
Crossref Google Scholar
27

Yang M, Zhang X, Guo L, Liu X, Wu J, Zhu H. Research progress for the clinical application of circulating tumor cells in prostate cancer diagnosis and treatment. Biomed Res Int. 2021; 2021: 6230826.
Crossref Google Scholar
28

Choughule A, Polampalli S, Amre P, Shinde S, Banavali S, Prabhash K, et al. Identification of PML/RARalpha fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization. Genet Mol Res. 2009; 8: 1-7.
Crossref Google Scholar
29

Brockman SR, Paternoster SF, Ketterling RP, Dewald GW. New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. Cancer Genet Cytogenet. 2003; 145: 144-51.
Crossref Google Scholar
30

Blanco EM, Curry CV, Lu XY, Sarabia SF, Redell MS, Lopez-Terrada DH, et al. Cytogenetically cryptic and FISH-negative PML/RARA rearrangement in acute promyelocytic leukemia detected only by PCR: an exceedingly rare phenomenon. Cancer Genet. 2014; 207: 48-9.
Crossref Google Scholar
31

Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Fioretos T, et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol. 1992; 82: 529-40.
Crossref Google Scholar
32

Tobal K, Liu Yin JA. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia. 1998; 12: 1349-54.
Crossref Google Scholar
33

William B, Coleman GJT. Molecular diagnostics for the clinical laboratorian. Totowa, NJ: Humana Press; 2006.
Crossref
34

Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 2001; 20: 7186-203.
Crossref Google Scholar
35

Rossi V, Levati L, Biondi A. Diagnosis and monitoring of PML-RARA-positive acute promyelocytic leukemia by qualitative RT-PCR. Methods Mol Med. 2006; 125: 115-26.
Crossref Google Scholar
36

Kommers IO, Bartley PA, Budgen B, Latham S, Beligaswatte A, Supple SG, et al. Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR. Leuk Lymphoma. 2017; 58: 1767-9.
Crossref Google Scholar
37

Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997; 11: 1605-9.
Crossref Google Scholar
38

Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001; 98: 1752-9.
Crossref Google Scholar
39

Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99: 4326-35.
Crossref Google Scholar
40

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127: 2391-405.
Crossref Google Scholar
41

Fathi AT, Chen YB. The role of FLT3 inhibitors in the treatment of FLT3 mutated acute myeloid leukemia. Eur J Haematol. 2016; 98: 330-6.
Crossref Google Scholar
42

Ma F, Liu P, Lei M, Liu J, Wang H, Zhao S, et al. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). Eur J Med Chem. 2016; 127: 72-86.
Crossref Google Scholar
43

Oh C, Kim H, Kang JS, Yun J, Sim J, Kim HM, et al. Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d] pyrimidine derivatives through structural modifications at the C2 and C6 positions. Bioorg Med Chem Lett. 2016; 27: 496-500.
Crossref Google Scholar
44

Beierl K, Tseng LH, Beierl R, Haley L, Gocke CD, Eshleman JR, et al. Detection of minor clones with internal tandem duplication mutations of FLT3 gene in acute myeloid leukemia using deltaPCR. Diagn Mol Pathol. 2013; 22: 1-9.
Crossref Google Scholar
45

Lin MT, Tseng LH, Beierl K, Hsieh A, Thiess M, Chase N, et al. Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 gene. Diagn Mol Pathol. 2013; 22: 149-55.
Crossref Google Scholar
46

Mills KI, Gilkes AF, Walsh V, Sweeney M, Gale R. Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3. Br J Haematol. 2005; 130: 203-8.
Crossref Google Scholar
47

Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003; 5: 96-102.
Crossref Google Scholar
48

Spencer DH, Abel HJ, Lockwood CM, Payton JE, Szankasi P, Kelley TW, et al. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. J Mol Diagn. 2013; 15: 81-93.
Crossref Google Scholar
49

He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, et al. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020; 33: 334-43.
Crossref Google Scholar
50

Abdelhamid E, Preudhomme C, Helevaut N, Nibourel O, Gardin C, Rousselot P, et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res. 2012; 36: 316-23.
Crossref Google Scholar
51

Scholl S, Loncarevic IF, Krause C, Kunert C, Clement JH, Hoffken K. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia. Leuk Res. 2005; 29: 849-53.
Crossref Google Scholar
52

Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, et al. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017; 92: 331-7.
Crossref Google Scholar
53

Bibault JE, Figeac M, Helevaut N, Rodriguez C, Quief S, Sebda S, et al. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget. 2015; 6: 22812-21.
Crossref Google Scholar
54

Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018; 2: 825-31.
Crossref Google Scholar
55

Thol F, Kolking B, Damm F, Reinhardt K, Klusmann JH, Reinhardt D, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012; 51: 689-95.
Crossref Google Scholar
56

Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131: 1275-91.
Crossref Google Scholar
57

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371: 2488-98.
Crossref Google Scholar
58

Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371: 2477-87.
Crossref Google Scholar
59

Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20: 1472-8.
Crossref Google Scholar
60

Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A. 2014; 111: 2548-53.
Crossref Google Scholar
61

Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia. 2007; 21: 998-1004.
Crossref Google Scholar
62

Mencia-Trinchant N, Hu Y, Alas MA, Ali F, Wouters BJ, Lee S, et al. Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations. J Mol Diagn. 2017; 19: 537-48.
Crossref Google Scholar
63

Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica. 2019; 104: 868-71.
Crossref Google Scholar
64

Press RD, Eickelberg G, Froman A, Yang F, Stentz A, Flatley EM, et al. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. Am J Hematol. 2019; 94: 902-12.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 19 Issue 1,
January 2022
Pages 4-13
DOI: 10.20892/j.issn.2095-3941.2020.0734
Cite this article:
Qin D. Molecular testing for acute myeloid leukemia. Cancer Biology & Medicine, 2022, 19(1): 4-13. https://doi.org/10.20892/j.issn.2095-3941.2020.0734

124

Views

1

Downloads

4

Crossref

6

Web of Science

6

Scopus

Altmetrics
Received: 01 December 2020
Accepted: 02 April 2021
Published: 21 March 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return